

Ref. No: 074110522
From: Commercial
Date: 11/05/22
Subject: Usage of intra-vitreous injections or implants

REQUEST & RESPONSE

I am analysing the usage of **intra-vitreous injections or implants** by the NHS. I would greatly appreciate if you could answer the following questions:

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2022:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

Drug	Number issued from Pharmacy
Aflibercept	588
Bevacizumab	0
Brolucizumab	8
Dexamethasone	62
Fluocinolone acetonide	0
Ranibizumab	721

2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2022.

Number of Injections/Implants: Jan to Apr 2022

Treatment	Eye Conditions		
	Wet Age-Related	Diabetic Macular	Retinal Vein

	Macular Degeneration wAMD	Degeneration DMO	Occulusion RVO
Aflibercept	425	74	46
Bevacizumab	2	1	
Brolucizumab	5	2	
Dexamethasone	2	12	13
Fluocinolone acetonide			
Ranibizumab	339	76	124